WorldCare Clinical, Inc. Appoints David Herron to Lead Business Development and Corporate Strategy

BOSTON, MA--(Marketwire - January 04, 2013) -

WorldCare Clinical, LLC (WCC), a leading imaging CRO focused on maximizing the precision and accuracy of independent assessments in clinical trials, today announced that David Herron has been appointed executive vice president of business development and corporate strategy. Herron brings extensive senior management experience and industry knowledge to WCC having worked in healthcare for more than twenty years. He will be responsible for all sales, marketing and corporate communications activities worldwide, including expanding relations with clients and partners, refining service offerings and driving the company’s strategic direction.

“The clinical trials imaging landscape is changing rapidly,” said Richard Walovitch, PhD, president of WorldCare Clinical, LLC. “Sponsors and regulatory agencies are requiring a more integrated clinical and scientific solution and David’s experience and leadership are key to facilitating this transition. His experience will be instrumental as we integrate new capabilities and services, such as our Endpoint Assessment Committee (EAC) services, into our business model.”

Prior to joining WCC, Herron was an executive in residence with a leading private equity firm focused exclusively in healthcare. Herron has extensive experience serving in a variety of senior management roles at CROs, a central imaging organization and healthcare information technology companies. He is also a seventeen-year veteran of the United States military serving in the Marine Corps and Adjutant General Corps USA. He was thrice decorated during Operations Desert Shield and Desert Storm. He is a distinguished graduate of Lipscomb and Vanderbilt Universities.

About WorldCare Clinical
WorldCare Clinical (WCC) is a leading imaging CRO that employs imaging expertise, innovative technology and operational excellence to maximize the precision and accuracy of a blinded independent central review of clinical trial data. Originally founded in 1992 by the Massachusetts General Hospital (MGH) Department of Radiology, WCC has evolved as an independent company while maintaining a strategic relationship with MGH. With a 20-year focus on imaging trials and their specific requirements, WCC provides sponsors with extensive medical, operational, and image management expertise in support of even the most complex study designs. For more information, visit www.wcclinical.com.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: Endpoint Assessment Committee EAC BICR blinded independent central review subjective endpoints